The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr.

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. ...

Neurocrine’s drug has a clear advantage, however, as it has been approved without the black box warning on depression and suicidal ideation that its rival must carry. Chief executive Kevin ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in people with obesity.

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Neurocrine successfully developed and received U.S. Food and Drug Administration approval in 2017 for valbenazine, a selective VMAT2 inhibitor, for use as the first drug ever developed for the ...